The Open University
Design, development and characterization of novel Globo-H-targeting CAR T cells for solid tumours cell therapy
Abstract
dc:description.abstractChimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of haematological malignancies; however, its efficacy in solid tumours remains limited due to multiple barriers, including the challenge of identifying tumour-specific targets that minimize on-target, off-tumour toxicities. In this thesis, we investigated Globo-H, a glycosphingolipid antigen abundantly expressed in several epithelial cancers - particularly of the gastrointestinal tract - but minimally detected in normal tissues, making it an attractive candidate target.<br></br><br></br> We engineered second-generation CAR T cells by cloning the MBr1-derived single-chain variable fragment (scFv), specific for Globo-H, into retroviral vectors incorporating either a CD28 or 4-1BB co-stimulatory domain. Following <i>ex vivo</i> expansion with IL-7 and IL-15, Globo-H CAR T cells were extensively characterized for their phenotypic and functional properties. <i>In vitro</i> assays demonstrated that both CAR constructs selectively recognized and eradicated Globo-H–positive tumour cell lines, while Globo-H-negative were not targeted. Despite comparable cytotoxic activity, the two CAR designs displayed significantly distinct phenotypic traits: CAR_41BB T cells were enriched in early differentiated subsets (T<sub>SCM</sub> and T<sub>CM</sub>), associated with long-term persistence, whereas CAR_CD28 T cells exhibited a more differentiated effector-memory phenotype, favouring rapid effector responses but reduced durability.<br></br><br></br> <i>In vivo</i>, infusion of Globo-H CAR T cells into xenografted NSG mice confirmed their capacity to home to tumours with a significant tumour growth suppression. Importantly, CAR_41BB T cells achieved durable tumour control with a promising safety profile, whereas CAR_CD28 T cells, although highly potent, were associated with systemic toxicities, highlighting the critical impact of co-stimulatory design on therapeutic outcome.<br></br><br></br> Collectively, these findings provide strong preclinical evidence that Globo-H CAR T cells can mediate robust antigen-specific anti-tumour activity in solid tumours, particularly gastric cancer and cholangiocarcinoma. Moreover, they highlight the translational potential of CAR_41BB T cells as a safer and more durable therapeutic strategy, paving the way for clinical development and evaluation in Globo-H–positive cancers.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Putti, Francesca
Rights
- Language dc:language
- en